33 drugs in Guangdong province went up 7.9% on average

After more than four months of rigorous screening, review, and demonstration, the price of the second batch of differential pricing medicines in Guangdong was formally announced on September 1. The reporter learned from the Guangdong Provincial Price Bureau that 33 drugs, including patented drugs, national confidential prescription drugs, and innovative drugs, were ultimately successful. Drug prices rose by an average of 7.9%, an increase of 2.9 points over the average of the first 36 differentially-priced drugs. Percentage. At present, the review results have been announced on the Guangdong Price Information Network and the Guangdong Provincial Drug Price Management Service Platform and are subject to social supervision.

Strict pricing

According to reports, there are 33 drugs in the second batch of differential pricing drugs, of which 23 drugs have averaged 8.3% on the basis of the government's uniform price, and the prices of 6 drugs have increased by an average of 6.8% on the basis of the highest retail guiding price. The price is lower than the highest retail guide price. In general, the average price increase for the batch of differential pricing drugs was 7.9%.

The relevant person of the Guangdong Provincial Price Bureau told reporters that from April 19 to May 7 this year, the Guangdong Provincial Price Bureau received a total of 162 differential pricing drugs for 162 enterprises that applied for online price information in Guangdong. Evaluation, quality system, drug characteristics, treatment costs, and price status After quantifying the 25 evaluation indicators in 5 aspects, the score is determined according to the score. Experts then propose specific recommended prices according to different levels, and finally remove the highest price according to the recommended price. And a lowest price, calculate the average as the proposed price.

In the public notice of the second batch of differential pricing drugs, the reporter found that out of the 33 differentially priced drugs publicly announced, 9 were sold for more than RMB 100. Among them, recombinant human platelet production by Shenyang Sansheng Pharmaceutical Co., Ltd. Is a patented drug, each priced at 1,175 yuan.

“Using the pricing means, for drugs with outstanding efficacy, good safety, and universal acceptance by the public, appropriate compensation for the reasonable costs of production and operations of enterprises and maintaining a reasonable level of benefits, in order to protect the effectiveness of drug use is the original intention and destination of China's drug price reform. After more than one month of rigorous review, the final 33 drugs broke through, which fully demonstrated the core of drug price reform to help and eliminate the inferior, said the above-mentioned sources.

Advantage factors

In the context of the nation's "dropping" price of drugs, many high-quality pharmaceuticals have not received substantial support from policies such as tendering and procurement, medical insurance, and high quality and favorable prices. Pharmaceutical companies do not receive corresponding profit returns, and innovation enthusiasm is frustrated. . To this end, the relevant national ministries and commissions have designated Guangdong Province as the first pilot province for drug price reform to discuss scientific pricing mechanisms. Today, two batches of differentially-priced drugs have come to the fore.

However, the reporter also noticed in the interview that, in the second batch of differential pricing applications, the company’s documented inadequate preparation of materials was still outstanding. Of the 196 drugs that were declared, 146 drugs were ineligible in the first instance. Among them, "incomplete information," "patent expired," "doesn't meet the domestic generic drugs," and "does not belong to January 1, 1993. "Japan patent law before the implementation of foreign patents," and other factors have become the main reason for declare the variety was not.

“The core of differential pricing lies in helping or eliminating the inferiority. It is not difficult to see from the review process of the first two batches of medicines that many companies’ products are not related to the absence of elements such as their qualification evidence, in addition to the product itself.” Some analysts pointed out that For example, in the second batch of differential pricing application, Cecilisina of Cedar Pharmaceuticals applied for the first generic drug, but the generic drug was listed in China in 1997. The registration time was before December 2001, and eventually it was due to non-compliance. The concept of the first generic drug was not approved. Another example is piperacillin sodium of Shuanghe Pharmaceutical, which also uses the first generic drug, but the drug does not exist in foreign countries according to the ratio of raw materials. There is no "generic drug," and the first copy is naturally not established.

The Guangdong Provincial Price Bureau stated that in addition to focusing on the quality and efficacy of the product, the “evidence” should also be spoken and the “evidence” should be taken as the criterion.

Air Sterilizer

Ningbo DOKEE Medical Technology Co., Ltd. , https://www.dokeemedical.com